抗黄热病毒人源单克隆抗体TY014的1期临床试验
该1期试验评估了全人源IgG1抗黄热病毒单克隆抗体TY014的安全性、药代动力学及减轻疫苗相关病毒血症的效果。1a期27名健康受试者中TY014剂量递增至20 mg/kg,1b期10名受试者双盲比较TY014与安慰剂。TY014未发现令人担忧的安全性信号,2 mg/kg起始剂量组5名受试者在输注后48小时均未检出病毒血症,提示潜在临床获益,需2期试验进一步评估。
要点
- TY014在1期试验中未发现令人担忧的安全性信号。
- 2 mg/kg TY014组5名受试者48小时均无YF17D-204病毒血症。
- TY014平均半衰期约12.8天,黄热疫苗相关症状较少。
核心结论
- TY014的1期试验未发现令人担忧的安全性信号,并提示潜在临床获益,需2期试验进一步评估。
研究设计与样本
- 1a期评估TY014安全性、副作用谱和药代动力学,27名健康受试者入组,22名完成剂量递增至最大20 mg/kg。
- 1b期双盲试验比较TY014与安慰剂在减轻 live yellow fever vaccine(YF17D-204;Stamaril)相关病毒血症中的效力,10名受试者入组。
主要发现
- 输注后1小时内不良事件:TY014组27名中1名发生,安慰剂组10名中0名发生。
- 试验期间至少1次不良事件:TY014组22名发生,安慰剂组8名发生。
- TY014平均半衰期约12.8天。
- 输注后48小时,2 mg/kg起始剂量组5名受试者均未检出YF17D-204病毒血症,且全程无病毒血症。
- 安慰剂组5名中2名在48小时检出病毒血症,另2名在72小时检出;黄热疫苗相关症状TY014组少于安慰剂组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Insufficient vaccine doses and the lack of therapeutic agents for yellow fever put global health at risk, should this virus emerge from sub-Saharan Africa and South America. METHODS: In phase 1a of this clinical trial, we assessed the safety, side-effect profile, and pharmacokinetics of TY014, a fully human IgG1 anti-yellow fever virus monoclonal antibody. In a double-blind, phase 1b clinical trial, we assessed the efficacy of TY014, as compared with placebo, in abrogating viremia related to the administration of live yellow fever vaccine (YF17D-204; Stamaril). The primary safety outcomes were adverse events reported 1 hour after the infusion and throughout the trial. The primary efficacy outcome was the dose of TY014 at which 100% of the participants tested negative for viremia within 48 hours after infusion. RESULTS: A total of 27 healthy participants were enrolled in phase 1a, and 10 participants in phase 1b. During phase 1a, TY014 dose escalation to a maximum of 20 mg per kilogram of body weight occurred in 22 participants. During phases 1a and 1b, adverse events within 1 hour after infusion occurred in 1 of 27 participants who received TY014 and in none of the 10 participants who received placebo. At least one adverse event occurred during the trial in 22 participants who received TY014 and in 8 who received placebo. The mean half-life of TY014 was approximately 12.8 days. At 48 hours after the infusion, none of the 5 participants who received the starting dose of TY014 of 2 mg per kilogram had detectable YF17D-204 viremia; these participants remained aviremic throughout the trial. Viremia was observed at 48 hours after the infusion in 2 of 5 participants who received placebo and at 72 hours in 2 more placebo recipients. Symptoms associated with yellow fever vaccine were less frequent in the TY014 group than in the placebo group. CONCLUSIONS: This phase 1 trial of TY014 did not identify worrisome safety signals and suggested potential clinical benefit, which requires further assessment in a phase 2 trial. (Funded by Tysana; ClinicalTrials.gov number, NCT03776786.).
引用
- Low JG, Ng JHJ, Ong EZ, et al. Phase 1 Trial of a Therapeutic Anti-Yellow Fever Virus Human Antibody. N Engl J Med. 2020. PMID: 32726531. doi:10.1056/NEJMoa2000226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。